SYNERGY: A Phase 1b/2 Study of Nenocorilant, a Selective Glucocorticoid Receptor Antagonist, Plus Nivolumab in Patients With Advanced Solid Malignancies
Saturday, May 30, 2026 1 min read
Key Takeaway: The SYNERGY study investigates the efficacy of nenocorilant combined with nivolumab in patients with advanced solid tumors. Presented by Dr. Omid Hamid at the American Society of Clinical Oncology Annual Meeting, this Phase 1b/2 trial aims to provide insights into this innovative treatment approach. The findings may contribute to new therapeutic strategies in oncology.
Price reaction · baseline $69.49 (2026-05-29 close) · clean, no other CORT news in the window
day 0 close · peak
+1.4%
Market Sentiment Analysis
POSITIVE FACTORS
The study explores a novel treatment combination for advanced solid malignancies.
Nenocorilant is a selective glucocorticoid receptor antagonist, which may offer new therapeutic options.
The presentation at a major oncology meeting highlights the significance of the research.
Full Press Release Details
Presented : American Society of Clinical Oncology Annual Meeting , 30 May 2026 , Chicago, IL
Presenter : Omid Hamid, MD
Scientific journal publications or scientific congress presentations may include information regarding investigational products or uses.
Download Poster
The post SYNERGY: A Phase 1b/2 Study of Nenocorilant, a Selective Glucocorticoid Receptor Antagonist, Plus Nivolumab in Patients With Advanced Solid Malignancies appeared first on Corcept Therapeutics .
Frequently Asked Questions
What is the SYNERGY study about?
The SYNERGY study investigates nenocorilant combined with nivolumab for advanced solid tumors.
Who presented the SYNERGY study?
The study was presented by Dr. Omid Hamid at the ASCO Annual Meeting.
What type of trial is the SYNERGY study?
It is a Phase 1b/2 clinical trial.
Where was the SYNERGY study presented?
It was presented at the American Society of Clinical Oncology Annual Meeting in Chicago.